← Back to Search

Buffering Agent

Exercise for Chronic Kidney Disease (Sym-CKD Trial)

Phase 1
Recruiting
Led By Jeanie Park, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Veterans with Stages III and IV Chronic Kidney Disease (CKD)
Veterans 18-75 years old, without kidney disease, as study controls
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 30 minutes
Awards & highlights

Sym-CKD Trial Summary

This trial is studying how well exercise training works in patients with CKD.

Who is the study for?
This trial is for veterans aged 18-75 with Stage III or IV Chronic Kidney Disease who exercise less than 40 minutes per week. It's also open to similar-aged veterans without kidney disease as controls. Participants must be able to follow the study plan and ride a stationary bike, but can't join if they have severe CKD, certain blood chemistry imbalances, drug/alcohol abuse issues, diabetic neuropathy, serious diseases affecting survival chances, severe anemia or heart problems.Check my eligibility
What is being tested?
The study aims to understand why patients with chronic kidney disease struggle with physical activity and experience high blood pressure during it. It tests how stretching exercises compare against no exercise (control), the effects of sodium bicarbonate supplementation versus placebo, and the benefits of regular exercise training.See study design
What are the potential side effects?
Possible side effects from participating in this trial could include muscle soreness or injury from exercising. Sodium bicarbonate may cause digestive discomfort like bloating or stomach pain.

Sym-CKD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a veteran with advanced chronic kidney disease.
Select...
I am a veteran aged 18-75 without kidney disease.

Sym-CKD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in muscle interstitial pH after exercise/stretching training
Change in muscle oxygenation after exercise/stretching training
Change in venoconstriction after exercise/stretching training
Secondary outcome measures
Change in Functional Sympatholysis
Change in Venoconstriction after Phenylephrine
Change in muscle interstitial pH after handgrip exercise

Sym-CKD Trial Design

5Treatment groups
Active Control
Placebo Group
Group I: Control to Exercise (Stretching) plus Sodium BicarbonateActive Control2 Interventions
Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each stretching session three times a week.
Group II: Exercise Training plus Sodium BicarbonateActive Control2 Interventions
Subjects with CKD will undergo exercise training on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each exercise session three times a week.
Group III: Exercise Training plus PlaceboActive Control2 Interventions
Subjects with CKD will undergo exercise training on a stationary bicycle,for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
Group IV: Healthy ControlActive Control1 Intervention
Healthy subjects without CKD will not receive any interventions.
Group V: Control to Exercise (Stretching) plus PlaceboPlacebo Group2 Interventions
Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,851 Previous Clinical Trials
47,817,423 Total Patients Enrolled
Emory UniversityLead Sponsor
1,652 Previous Clinical Trials
2,572,768 Total Patients Enrolled
Jeanie Park, MDPrincipal Investigator - Emory University
Emory University Hospital, Emory University Hospital Midtown, Select Specialty Hospital-Atlanta
University Of Alabama School Of Medicine (Medical School)
4 Previous Clinical Trials
464 Total Patients Enrolled

Media Library

Sodium Bicarbonate (Buffering Agent) Clinical Trial Eligibility Overview. Trial Name: NCT02411773 — Phase 1
Chronic Kidney Disease Research Study Groups: Control to Exercise (Stretching) plus Sodium Bicarbonate, Control to Exercise (Stretching) plus Placebo, Exercise Training plus Sodium Bicarbonate, Exercise Training plus Placebo, Healthy Control
Chronic Kidney Disease Clinical Trial 2023: Sodium Bicarbonate Highlights & Side Effects. Trial Name: NCT02411773 — Phase 1
Sodium Bicarbonate (Buffering Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02411773 — Phase 1
~27 spots leftby Jun 2027